Acute myeloid leukemia (AML) can be diagnosed at any age and treatment, which can be given with supportive and/or curative intent, is considered expensive compared with that for other cancers. Despite this, no long-term predictive models have been developed for AML, mainly because of the complexities associated with this disease
Over half of patients diagnosed with acute myeloid leukemia (AML) are 65 years or older. Using the l...
The 5-year relative survival of adults diagnosed with acute myeloid leukaemia (AML) was less than 10...
Purpose: To estimate five-year survival and the proportion of patients ‘cured’ of acute myeloid Leuk...
Acute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought to be unfit...
Acute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought to be unfit...
Background: The treatment of acute myeloid leukemia (AML) is moving towards personalized medicine. H...
Biological and non-biological variables unrelated to acute myeloid leukemia (AML) preclude standard ...
Recent advances in non-intensive therapy (non-IC) have demonstrated the potential for improved outco...
Item does not contain fulltextLarge, comprehensive population-based studies in acute myeloid leukemi...
No recent full-text-based systematic review has been published to examine economic evidence around a...
The 5-year relative survival of adults diagnosed with acute myeloid leukaemia (AML) was less than 10...
Background: AML is one of the most common and acute diseases among the types of leukaemia. The treat...
Biological and non-biological variables unrelated to acute myeloid leukemia (AML) preclude standard ...
The incidence of acute myeloid leukaemia (AML) increases with age and mortality exceeds 90% when dia...
We evaluated temporal trends in survival of Swedish acute myeloid leukemia (AML) patients diagnosed ...
Over half of patients diagnosed with acute myeloid leukemia (AML) are 65 years or older. Using the l...
The 5-year relative survival of adults diagnosed with acute myeloid leukaemia (AML) was less than 10...
Purpose: To estimate five-year survival and the proportion of patients ‘cured’ of acute myeloid Leuk...
Acute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought to be unfit...
Acute myeloid leukemia (AML) is most common in the elderly, and most elderly are thought to be unfit...
Background: The treatment of acute myeloid leukemia (AML) is moving towards personalized medicine. H...
Biological and non-biological variables unrelated to acute myeloid leukemia (AML) preclude standard ...
Recent advances in non-intensive therapy (non-IC) have demonstrated the potential for improved outco...
Item does not contain fulltextLarge, comprehensive population-based studies in acute myeloid leukemi...
No recent full-text-based systematic review has been published to examine economic evidence around a...
The 5-year relative survival of adults diagnosed with acute myeloid leukaemia (AML) was less than 10...
Background: AML is one of the most common and acute diseases among the types of leukaemia. The treat...
Biological and non-biological variables unrelated to acute myeloid leukemia (AML) preclude standard ...
The incidence of acute myeloid leukaemia (AML) increases with age and mortality exceeds 90% when dia...
We evaluated temporal trends in survival of Swedish acute myeloid leukemia (AML) patients diagnosed ...
Over half of patients diagnosed with acute myeloid leukemia (AML) are 65 years or older. Using the l...
The 5-year relative survival of adults diagnosed with acute myeloid leukaemia (AML) was less than 10...
Purpose: To estimate five-year survival and the proportion of patients ‘cured’ of acute myeloid Leuk...